Chapter 8. Higher-order Structure Characterization and Comparability Assessments for Peptides

Renáta Varga, A. Rane
{"title":"Chapter 8. Higher-order Structure Characterization and Comparability Assessments for Peptides","authors":"Renáta Varga, A. Rane","doi":"10.1039/9781788016445-00274","DOIUrl":null,"url":null,"abstract":"There is increased interest in peptides in pharmaceutical research and development owing to their superior characteristics over small molecules in terms of high selectivity, efficacy and safety and also over large biomolecules in terms of less complexity and the associated cost. However, peptides sit between these two well-studied and understood groups of therapeutics, challenging scientists in designing characterization and comparability studies to cover all analytical aspects. There is a vital part of chemistry, manufacturing and control (CMC) in peptide drug development describing the structure and characterization of the molecule itself and in the case of a generic development comparing its structure with that of a reference product. Considering the complexity in terms of multiple structural elements of peptides, similarly to proteins, these sections highlight the higher-order structure of peptides during development. This chapter focuses on the description of the higher-order structure elements of peptides and the potential analytical methodologies for characterization and to present the main differences and challenges when studying peptides compared with large proteins. At the end of the chapter, a recommended study design of higher-order structure characterization and comparability of generic peptides is presented. Note that in this chapter peptides are considered to be, by definition, to contain fewer than 100 amino acid residues and are well distinguished from proteins.","PeriodicalId":20009,"journal":{"name":"Peptide Therapeutics","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Peptide Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1039/9781788016445-00274","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

There is increased interest in peptides in pharmaceutical research and development owing to their superior characteristics over small molecules in terms of high selectivity, efficacy and safety and also over large biomolecules in terms of less complexity and the associated cost. However, peptides sit between these two well-studied and understood groups of therapeutics, challenging scientists in designing characterization and comparability studies to cover all analytical aspects. There is a vital part of chemistry, manufacturing and control (CMC) in peptide drug development describing the structure and characterization of the molecule itself and in the case of a generic development comparing its structure with that of a reference product. Considering the complexity in terms of multiple structural elements of peptides, similarly to proteins, these sections highlight the higher-order structure of peptides during development. This chapter focuses on the description of the higher-order structure elements of peptides and the potential analytical methodologies for characterization and to present the main differences and challenges when studying peptides compared with large proteins. At the end of the chapter, a recommended study design of higher-order structure characterization and comparability of generic peptides is presented. Note that in this chapter peptides are considered to be, by definition, to contain fewer than 100 amino acid residues and are well distinguished from proteins.
第八章。多肽的高阶结构表征和可比性评价
由于多肽在高选择性、有效性和安全性方面优于小分子,在复杂性和相关成本方面也优于大分子,因此在药物研究和开发中对多肽的兴趣越来越大。然而,多肽位于这两种被充分研究和理解的治疗药物之间,这对科学家设计表征和可比性研究以涵盖所有分析方面提出了挑战。在多肽药物开发中,化学、制造和控制(CMC)的一个重要部分是描述分子本身的结构和特性,并在仿制药开发的情况下将其结构与参考产品的结构进行比较。考虑到多肽的多个结构元素的复杂性,类似于蛋白质,这些部分突出了多肽在发育过程中的高阶结构。本章重点描述肽的高阶结构元素和潜在的表征分析方法,并介绍在研究肽与大蛋白质相比时的主要差异和挑战。在本章的最后,提出了通用肽的高阶结构表征和可比性的推荐研究设计。请注意,在本章中,根据定义,多肽被认为包含少于100个氨基酸残基,并且与蛋白质有很好的区别。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信